Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22309754 | 0.90 | MET (0.58) | METNQO2CXCR1HRH3MAOA | |
| SCHEMBL12547598 | 0.89 | MET (0.57) | METNQO2CXCR1HRH3MAP4K1 | |
| SCHEMBL31495087 | 0.89 | MET (0.57) | METNQO2CXCR1HRH3MAOA | |
| SCHEMBL22310407 | 0.86 | CCNA2 (0.46) | METNQO2EP300 | |
| SCHEMBL12547624 | 0.85 | MAP4K1 (0.44) | METNQO2CHRM3MAP4K1 | |
| SCHEMBL13449240 | 0.85 | MET (0.53) | METNQO2CHRM3CXCR1HRH3 | |
| SCHEMBL31495102 | 0.85 | MET (0.53) | METNQO2CHRM3CXCR1HRH3 | |
| SCHEMBL2223511 | 0.84 | MET (0.52) | METNQO2CHRM3CXCR1HRH3 | |
| SCHEMBL23344107 | 0.83 | MET (0.54) | METNQO2CXCR1HRH3L3MBTL1 | |
| SCHEMBL21322203 | 0.83 | MET (0.53) | METNQO2CXCR1HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599885-A2 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-20240277711-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MERCK PATENT GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4346829-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | Merck Patent GmbH (DE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794541-A | Compounds for the treatment of glioblastoma | 默克专利股份公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022253935-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MERCK PATENT GMBH (DE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022063869-A2 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | MERCK PATENT GMBH (DE) | 2022-03-31 | — | — | WO | disclosed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9403799-B2 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | MERCK PATENT GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403799-B2 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | MERCK PATENT GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| EP-2164844-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164843-A1 | PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007074-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007074-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277711-A1 | COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA | MET, MGMT, EGFR | MET 1/4885NQO2 3689/4885CHRM3 4397/4885 |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MET, MERTK, ABL1 | MET 1/4885NQO2 1075/4885CHRM3 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.